IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2023
Aggregated presentation by day and by market Name of issuer Identification code of issuer (Legal…
Aggregated presentation by day and by market Name of issuer Identification code of issuer (Legal…
Publication of a Transparency Notification Received from Armistice Capital, LLC Liege, Belgium, 12 September 2023…
Enhancements to Lumen Field, Coach-to-Coach Private Network, and increased availability of 5G Home Internet support…
Tighter Pro Tools integration with Media Composer and prominent partner tools accelerate production of rich…
New product introductions and demonstrations harness artificial intelligence and third-party integrations to accelerate television, film…
Innovative AI Features Optimize Monetization Through Churn Prediction and Intelligent Payment Retry Features SUNNYVALE, Calif.,…
South Perth, Australia–(Newsfile Corp. – September 12, 2023) – Advanced Health Intelligence Ltd (ASX: AHI)…
SAN FRANCISCO, CA, Sep 12, 2023 – (ACN Newswire) – Anglepoint, the industry leader in…
HONG KONG, Sep 12, 2023 – (ACN Newswire) – Asia’s leading fashion event CENTRESTAGE (Hong…
PARIS, FRANCE, Sep 12, 2023 – (ACN Newswire) – Ad Scientiam, a global leader in…
DALLAS & FORT WORTH, Texas–(BUSINESS WIRE)–Mouser Electronics, Inc., the authorized global distributor with the newest…
Legal Industry Veteran, Christina Wojcik to Lead LexFusion’s Corporate Legal Operations, Commercial Transactions, and Innovation…
Daniel Villarreal, Philip Fritsche, and Ryan Bailey join HamptonRock to lead the growth and development…
Easy-to-use eyewear retail solution captures customers’ precise facial measurements to fit frames and elevate the…
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage…
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage…
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild…
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild…
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
PALO ALTO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…